NMDAR Down-Regulation: Dual – Hit Molecular Target For COPD – Depression Comorbidity

Uriel Heresco-Levy,Jacob Haviv,Yehezkel Caine
DOI: https://doi.org/10.2147/jir.s487650
IF: 4.5
2024-10-24
Journal of Inflammation Research
Abstract:Uriel Heresco-Levy, 1, 2 Jacob Haviv, 1 Yehezkel G Caine 1 1 Herzog Medical Center, Jerusalem, Israel; 2 Psychiatry Department, Hadassah Medical School, Hebrew University, Jerusalem, Israel Correspondence: Uriel Heresco-Levy, Herzog Medical Center, POBox 3900, Jerusalem, 91305, Israel, Tel +972-2-5316906, Fax +972-26075653, Email Chronic obstructive pulmonary disease (COPD) is a chronic lung disease characterized by sustained airflow limitation that represents one of the main causes of disability in modern society. Depression affects approximately 40% of COPD patients. Both COPD and depression are associated with chronic systemic inflammation and their comorbidity represents a critical unmet treatment need. N-methyl-D-aspartate glutamatergic receptors (NMDAR) are well characterized in the central nervous system (CNS) and widely expressed in lung tissue and inflammation-related cells. Accumulating evidence indicates that pathologic NMDAR up-regulation, leading to pro-inflammatory pathways activation and tissue damage, may play a crucial role in chronic lung injury as well as in depression. D-cycloserine, a bacteriostatic antibiotic used since the 1950's in tuberculosis, acts at therapeutic dosages also as a NMDAR functional antagonist and has antidepressant and anti-inflammatory effects. We hypothesize that NMDAR down-regulation may represent a unified molecular target for the treatment of COPD – depression comorbidity and may simultaneously alleviate both respiratory and depression symptomatology. We postulate that D-cycloserine treatment may achieve these dual – hit objectives and envisage that our hypotheses may apply to additional inflammation disorders that are frequently accompanied by depression. Keywords: inflammation, depression, chronic obstructive pulmonary disease, N-methyl-D-aspartate receptor, D-cycloserine Prolonged lung disease, inflammation and respiratory dysfunction are often accompanied by depression. Chronic obstructive pulmonary disease (COPD) is a slowly-developing multicomponent incurable disorder. Estimated COPD prevalence in people aged 40 years and older ranges between 7.4% and 12.6%. 1 Depression affects about 40% of COPD patients and one in four individuals with COPD-depression comorbidity experience an unfavorable illness course. 2 The relationship between COPD and depression is likely bidirectional and is mediated in part by low-grade inflammation. Elevated levels of inflammatory biomarkers have been documented in both late-life depression and COPD and may contribute to the association of depression with pulmonary obstruction. 3 Drugs commonly used to treat COPD, eg glucocorticoids and bronchodilators, target different receptorial systems, have significant side effects, and do not alleviate depression. Add-on selective serotonin reuptake inhibitors (SSRIs) and serotonin and norepinephrine reuptake inhibitors (SNRIs), are employed for this indication. However, the efficacy of serotonergic antidepressants in COPD patients remains controversial. In a large cohort of older adults with validated COPD, new SSRI/SNRIs users experienced a higher risk of hospitalization, emergency care visits, COPD or pneumonia-related mortality and all-cause mortality when compared with non-users. 4 Proposed mechanisms by which serotonergic antidepressants may cause harm in COPD include induction of sleepiness leading to decreased oxygen and increased carbon dioxide levels, lowering of infection threshold by an unfavorable impact on immune cell function and reduction of apoptotic cell clearance, which could lead to COPD exacerbation. 2,5 N-methyl-D-aspartate receptors (NMDAR) are cation channel glutamate (Glu) receptors widely expressed and well characterized in the central nervous system (CNS) that are well acknowledged to play a crucial role in brain physiological functions, excitotoxicity and neuropsychiatric disorders. Nevertheless, accumulating evidence suggests that Glu also acts as a signaling molecule outside the CNS, with an emerging role as an immune modulator. 6–9 In line with this concept, functional glutamatergic signaling and NMDAR expression have been found extensively in non-neuronal tissues, including lungs, kidneys, heart, pancreatic β cells, lymphocytes and inflammation-related cells. Moreover, physiological levels of NMDAR activation are of paramount importance. Under pathological conditions, extracellular Glu concentrations are increased by abnormal release and/or clearance. The resulting NMDAR over-activation triggers rapid Ca 2+ influx in the cell that may lead to pro-inflammatory signaling pathway activation ultimately resulting in cell damage and organ dysfunction. 5,6 We hypothesize that NMDAR may represent a unified molecular tar -Abstract Truncated-
immunology
What problem does this paper attempt to address?